p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis
Cancer Cell International,
Abstract Background Identifying molecular biomarkers for predicting responses to anti-cancer drugs can enhance treatment…